Erteberel - Eli Lilly

Drug Profile

Erteberel - Eli Lilly

Alternative Names: LY 500307; SERBA-1

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Indiana University; National Institute of Mental Health
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Clinical Phase Unknown Mood disorders
  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 04 Oct 2018 Clinical trials in Mood disorders in USA (unspecified route) (NCT03689543)
  • 12 Sep 2018 Phase-II development for Schizophrenia is ongoing in USA (NCT01874756)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top